fluarix
Vaccineexperimental
Influenza vaccines, colloquially known as flu shots or the flu jab, are vaccines that protect against infection by influenza viruses. New versions of the vaccines are developed twice a year, as the influenza virus rapidly changes. While their effectiveness varies from year to year, most provide modest to high protection against influenza. Vaccination against influenza began in the 1930s, with large-scale availability in the United States beginning in 1945. — Wikipedia
Clinical trial activity
62 trials · 38 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
46
Phase 3
28
Phase 4
7
Earliest trial started Sep 1, 2002 (NCT00731029)
Timeline
Indications
Approved for
Mechanism of action
- Influenza A virusImmunity, active
Influenza A virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaInfluenza vaccine ↗
Also known as
- fluarix
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06602024 | Phase 3 | Sep 16, 2024 | Moderna Therapeutics |
| NCT05827926 | Phase 1/Phase 2 (Phase 2) | Apr 14, 2023 | Moderna Therapeutics |
| NCT05170399 | Phase 4 | Sep 14, 2022 | National Heart, Lung, and Blood Institute (NHLBI) |
| NCT03722589 | Phase 4 | Sep 12, 2018 | Baylor Scott and White, Centers for Disease Control and Prevention (CDC), Kaiser Permanente |
| NCT03339713 | Phase 2 | Dec 7, 2017 | Janssen Pharmaceutica NV |
| NCT03133936 | N/A | Dec 1, 2016 | University of Rochester |
| NCT02707692 | N/A | Aug 1, 2016 | National Institute of Allergy and Infectious Diseases (NIAID), University of California, San Diego |
| NCT02962908 | Phase 2 | Aug 1, 2016 | Government of Norway, Isala Clinics, Zwolle, The Netherlands, Robert Koch Institut, SEEK, University of Groningen |
| NCT02658409 | Phase 3 | Nov 1, 2015 | Chonnam National University, Columbia University, Green Cross Corporation, Hallym University, Inha University, Korea University, Kyungpook University, Soonchunhyang University |
| NCT02557802 | N/A | Oct 1, 2015 | University of London |
| NCT02369341 | Phase 3 | Apr 1, 2015 | GlaxoSmithKline |
| NCT02297542 | Phase 4 | Oct 1, 2014 | Health Sciences North Research Institute, University of Connecticut |
| NCT02148328 | Phase 1 | May 1, 2014 | Crucell |
| NCT01959945 | Phase 3 | Nov 1, 2013 | Protein Sciences Corp |
| NCT01878812 | Phase 3 | Jul 1, 2013 | GlaxoSmithKline |
| NCT01884519 | Phase 3 | Jul 1, 2013 | GlaxoSmithKline |
| NCT02330003 | Phase 1 | May 1, 2013 | Il-Yang Pharm. Co., Ltd., Yonsei University |
| NCT01730378 | Phase 4 | Dec 1, 2012 | GlaxoSmithKline |
| NCT01711736 | Phase 3 | Nov 1, 2012 | GlaxoSmithKline |
| NCT01702454 | Phase 3 | Oct 1, 2012 | GlaxoSmithKline |
Showing 20 of 62 trials
Page 1 / 4
Organizations
Research & Development (38)
38 organizations
Page 1 / 2